Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.
NVO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novo Nordisk A S. To summarize, we found that Novo Nordisk A S ranked in the 65th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for NVO, they are:
In the past 4.74 years, Novo Nordisk A S has a compound free cash flow growth rate of 0.03%; that's higher than only 23.4% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than just 3.84% of the free cash flow producing stocks we're observing.
NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 57.11% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See FMS, DVA, FZMD, PNTG, and DGX.
Novo Nordisk A/S (NVO) 39th Annual JPMorgan Virtual Healthcare Conference January 12, 2021 09:10 AM ET Company Participants Lars Fruergaard Jørgensen - CEO Conference Call Participants Richard Vosser - JPMorgan Presentation Richard Vosser Good morning. Good afternoon. Welcome to the 39th JPMorgan Healthcare Conference. I’m Richard Vosser, European Pharma Analyst...
SA Transcripts on Seeking Alpha | January 12, 2021
CMI published a business research report on “Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2020–2027”. Hemophilia Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand
DUBLIN--(BUSINESS WIRE)--The "Biotechnology Services Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Biotechnology Services Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biotechnology services market. Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo N
The global Special Purpose Needles Market research report thoroughly explains each and every aspect related to the Special Purpose Needles Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to